Key metrics including vessel density, skeletonized vessel density, average vessel radius, and our novel metric named Macular Vascular Volume (MVV), were extracted to assess consistency across two-time points, namely pre- and post-treatment with anti-Vascular Endothelial Growth Factor (anti-VEGF) agents and hence before and after resolution of macular oedema. This evidence concerns the gene VEGFA and macular retinal edema.